X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA FRESENIUS KABI ONCO. GLENMARK PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 20.3 22.1 91.8% View Chart
P/BV x 3.6 3.1 116.7% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 GLENMARK PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
FRESENIUS KABI ONCO.
Mar-13
GLENMARK PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs993176 564.2%   
Low Rs72979 929.0%   
Sales per share (Unadj.) Rs325.537.7 863.8%  
Earnings per share (Unadj.) Rs39.35.1 771.5%  
Cash flow per share (Unadj.) Rs48.76.7 723.8%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs159.242.5 374.2%  
Shares outstanding (eoy) m282.17158.23 178.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.63.4 78.3%   
Avg P/E ratio x21.925.0 87.7%  
P/CF ratio (eoy) x17.718.9 93.5%  
Price / Book Value ratio x5.43.0 180.8%  
Dividend payout %5.10-   
Avg Mkt Cap Rs m242,99120,135 1,206.8%   
No. of employees `00013.01.2 1,125.6%   
Total wages/salary Rs m16,408703 2,333.3%   
Avg. sales/employee Rs Th7,083.95,176.2 136.9%   
Avg. wages/employee Rs Th1,265.4610.4 207.3%   
Avg. net profit/employee Rs Th855.1699.6 122.2%   
INCOME DATA
Net Sales Rs m91,8575,963 1,540.4%  
Other income Rs m37418 2,075.8%   
Total revenues Rs m92,2305,981 1,542.1%   
Gross profit Rs m20,3671,430 1,424.2%  
Depreciation Rs m2,644258 1,025.1%   
Interest Rs m2,373-26 -9,127.7%   
Profit before tax Rs m15,7241,216 1,292.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-810-68 1,188.7%   
Tax Rs m3,827342 1,118.3%   
Profit after tax Rs m11,088806 1,375.8%  
Gross profit margin %22.224.0 92.5%  
Effective tax rate %24.328.1 86.5%   
Net profit margin %12.113.5 89.3%  
BALANCE SHEET DATA
Current assets Rs m68,7465,102 1,347.5%   
Current liabilities Rs m27,0272,385 1,133.0%   
Net working cap to sales %45.445.6 99.7%  
Current ratio x2.52.1 118.9%  
Inventory Days Days85150 56.7%  
Debtors Days Days96113 84.3%  
Net fixed assets Rs m24,1325,148 468.8%   
Share capital Rs m282158 178.4%   
"Free" reserves Rs m44,6436,556 681.0%   
Net worth Rs m44,9256,732 667.4%   
Long term debt Rs m45,363952 4,764.1%   
Total assets Rs m117,63910,388 1,132.4%  
Interest coverage x7.6-45.8 -16.7%   
Debt to equity ratio x1.00.1 713.9%  
Sales to assets ratio x0.80.6 136.0%   
Return on assets %11.47.5 152.4%  
Return on equity %24.712.0 206.2%  
Return on capital %19.114.6 131.1%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m56,1525,298 1,059.9%   
Fx outflow Rs m8,0841,772 456.2%   
Net fx Rs m48,0683,525 1,363.5%   
CASH FLOW
From Operations Rs m6,5741,274 516.0%  
From Investments Rs m-7,124-1,204 591.6%  
From Financial Activity Rs m5,432-196 -2,769.8%  
Net Cashflow Rs m1,992-126 -1,577.5%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 6.9 0.3 2,300.0%  
FIIs % 34.4 9.6 358.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 9.1 115.4%  
Shareholders   56,727 42,599 133.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   UNICHEM LAB  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 21, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS